Changyu Pharmaceutical has completed RMB 250 million in Series D financing.

36Kr has learned that, according to sources from Qidian Capital, Changyu Pharmaceutical has announced the completion of a RMB 250 million Series D financing. This round of financing is jointly led by Efung Capital and HighTide Investment, with the joint participation of other institutions including Jiaxing Yuanfan and Real Capital Global. Qidian Capital has continuously acted as the financial advisor. The funds raised in this round will be mainly used for the Phase III acute pain clinical research of Changyu Pharmaceutical's debut product XG005 in the United States, and support the continuous development of the company's core product pipeline and its globalization advancement.